Insider Selling: ProKidney Corp. (NASDAQ:PROK) SVP Sells 16,438 Shares of Stock

ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber sold 16,438 shares of ProKidney stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $2.51, for a total value of $41,259.38. Following the transaction, the senior vice president now directly owns 155,194 shares in the company, valued at approximately $389,536.94. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

ProKidney Stock Down 7.0 %

Shares of PROK stock traded down $0.19 during trading hours on Tuesday, reaching $2.53. 1,149,737 shares of the company’s stock were exchanged, compared to its average volume of 688,547. ProKidney Corp. has a fifty-two week low of $1.12 and a fifty-two week high of $13.51. The stock has a market capitalization of $580.24 million, a P/E ratio of -4.63 and a beta of 1.08. The business has a fifty day moving average price of $1.63 and a 200-day moving average price of $1.74.

ProKidney (NASDAQ:PROK) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. As a group, research analysts expect that ProKidney Corp. will post -0.65 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PROK. Morgan Stanley began coverage on ProKidney in a research note on Thursday, March 7th. They issued an “equal weight” rating and a $3.00 price target for the company. Bank of America cut ProKidney from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 2nd.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in shares of ProKidney in the third quarter valued at $78,000. Jump Financial LLC acquired a new position in shares of ProKidney in the third quarter valued at $216,000. Finally, Federated Hermes Inc. grew its holdings in shares of ProKidney by 10,984.7% during the fourth quarter. Federated Hermes Inc. now owns 113,286 shares of the company’s stock worth $202,000 after purchasing an additional 112,264 shares during the last quarter. 51.59% of the stock is currently owned by institutional investors and hedge funds.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.